1
|
Henry KL, Kellner D, Bajrami B, Anderson JE, Beyna M, Bhisetti G, Cameron T, Capacci AG, Bertolotti-Ciarlet A, Feng J, Gao B, Hopkins B, Jenkins T, Li K, May-Dracka T, Murugan P, Wei R, Zeng W, Allaire N, Buckler A, Loh C, Juhasz P, Lucas B, Ennis KA, Vollman E, Cahir-McFarland E, Hett EC, Ols ML. CDK12-mediated transcriptional regulation of noncanonical NF-κB components is essential for signaling. Sci Signal 2018; 11:eaam8216. [PMID: 30065029 DOI: 10.1126/scisignal.aam8216] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Members of the family of nuclear factor κB (NF-κB) transcription factors are critical for multiple cellular processes, including regulating innate and adaptive immune responses, cell proliferation, and cell survival. Canonical NF-κB complexes are retained in the cytoplasm by the inhibitory protein IκBα, whereas noncanonical NF-κB complexes are retained by p100. Although activation of canonical NF-κB signaling through the IκBα kinase complex is well studied, few regulators of the NF-κB-inducing kinase (NIK)-dependent processing of noncanonical p100 to p52 and the subsequent nuclear translocation of p52 have been identified. We discovered a role for cyclin-dependent kinase 12 (CDK12) in transcriptionally regulating the noncanonical NF-κB pathway. High-content phenotypic screening identified the compound 919278 as a specific inhibitor of the lymphotoxin β receptor (LTβR), and tumor necrosis factor (TNF) receptor superfamily member 12A (FN14)-dependent nuclear translocation of p52, but not of the TNF-α receptor-mediated nuclear translocation of p65. Chemoproteomics identified CDK12 as the target of 919278. CDK12 inhibition by 919278, the CDK inhibitor THZ1, or siRNA-mediated knockdown resulted in similar global transcriptional changes and prevented the LTβR- and FN14-dependent expression of MAP3K14 (which encodes NIK) as well as NIK accumulation by reducing phosphorylation of the carboxyl-terminal domain of RNA polymerase II. By coupling a phenotypic screen with chemoproteomics, we identified a pathway for the activation of the noncanonical NF-κB pathway that could serve as a therapeutic target in autoimmunity and cancer.
Collapse
Affiliation(s)
- Kate L Henry
- Biogen, 225 Binney Street, Cambridge, MA 02142, USA
- Department of Pharmacology, Boston University School of Medicine, Boston, MA 02118, USA
| | | | | | - John E Anderson
- Biogen, 225 Binney Street, Cambridge, MA 02142, USA
- Department of Pharmacology, Boston University School of Medicine, Boston, MA 02118, USA
| | | | | | - Tom Cameron
- Biogen, 225 Binney Street, Cambridge, MA 02142, USA
| | | | | | - Jun Feng
- Biogen, 225 Binney Street, Cambridge, MA 02142, USA
| | - Benbo Gao
- Biogen, 225 Binney Street, Cambridge, MA 02142, USA
| | | | | | - Kejie Li
- Biogen, 225 Binney Street, Cambridge, MA 02142, USA
| | | | | | - Ru Wei
- Biogen, 225 Binney Street, Cambridge, MA 02142, USA
| | - Weike Zeng
- Biogen, 225 Binney Street, Cambridge, MA 02142, USA
| | - Norm Allaire
- Biogen, 225 Binney Street, Cambridge, MA 02142, USA
| | - Alan Buckler
- Biogen, 225 Binney Street, Cambridge, MA 02142, USA
| | | | - Peter Juhasz
- Biogen, 225 Binney Street, Cambridge, MA 02142, USA
| | - Brian Lucas
- Biogen, 225 Binney Street, Cambridge, MA 02142, USA
| | | | | | | | - Erik C Hett
- Biogen, 225 Binney Street, Cambridge, MA 02142, USA.
| | | |
Collapse
|